Everads Therapy
Israel’s Everads Therapy is a biotech startup developing optimized retinal therapies by leveraging its novel suprachoroidal delivery technology. The firm released the initial clinical results from a first-in-human study of its platform for non-surgical delivery of therapeutics to the back of the eye via the suprachoroidal space.
Initial clinical results from a first-in-human study were presented at the 24th EURETINA Congress in Barcelona. The study (NCT06314217) is an open-label safety and performance trial that employs the Everads Injector to deliver a triamcinolone acetonide suspension suprachoroidally for the treatment of patients with diabetic macular edema (DME). The presentation, titled “A Novel Suprachoroidal Delivery Technology: Results from a First in Human Pilot Study – Cohort 1,” is available as an e-poster and will be published on the company’s website following the congress.
Yoreh Barak, MD, Head of Retina at the Department of Ophthalmology at Rambam Medical Center and the study’s Principal Investigator, stated, “The data reported today confirm the effectivity, ease of use and tolerability of the Everads Injector for suprachoroidal delivery. The ability for an individual physician in an office setting to deliver drug non-surgically via this promising administration route could lead to the development of more effective and less invasive treatments for posterior segment eye diseases.”
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Results from the pre-specified first cohort of patients were cleared by the Ministry of Health, and the company is now recruiting patients into its next cohort. Full results of the clinical trial are expected to be presented at an upcoming medical congress.
“We are excited to report promising results that clearly validate our technology in a clinical setting,” added Moshe Weinstein, Everads’ CEO. “These data will be used to support the clinical trial applications of our license partners and our internal programs, enabling suprachoroidal delivery of next-generation treatments for retinal diseases.”
Founded in 2017, Everads Therapy is a small early-stage life sciences company developing the next generation of retinal treatment delivery technologies. The company says that its goal is to overcome significant challenges in current treatment methodologies for retinal and macular diseases, Everads’ delivery system offers the promise of improving the efficacy and safety of existing and potential drug therapies. Everads Therapy operates within the RAD Biomed incubator in Tel Aviv, Israel. Its underlying technologies have been licensed from the Sheba Medical Center at Tel Hashomer.
